We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
+ I-Premise
low I-Premise
- I-Premise
dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5 I-Premise
- I-Premise
FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
post I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise

Approximately O
30 O
% O
of O
lung O
cancer O
cases O
are O
diagnosed O
in O
patients O
> O
70 O
years O
of O
age O
. O

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

This O
study O
focussed O
on O
the O
QoL O
in O
patients O
after O
oesophagectomy O
for O
cancer O
, O
comparing O
the O
method O
of O
reconstruction O
( O
narrow O
gastric O
tube O
vs O
whole O
stomach O
) O
. O

No B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28 O
. O
5 O
% O
) O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90 O
- O
100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

Multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
P I-Premise
values I-Premise
< I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise

We O
obtained O
quality O
- O
of O
- O
life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
"""" O
; O
"""" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Gross B-Premise
- B-Premise
total B-Premise
removal I-Premise
( I-Premise
GTR I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
SS I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
SN I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24 I-Premise
- I-Premise
hour I-Premise
infusion I-Premise
. I-Premise

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

The O
primary O
end O
- O
point O
was O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

In O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
HDC O
for O
high O
- O
risk O
breast O
cancer O
patients O
, O
QOL O
studies O
with O
a O
longer O
follow O
- O
up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade O
- O
off O
implied O
by O
HDC O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
QOL O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O

The B-Premise
FFM I-Premise
\/ I-Premise
FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
between I-Premise
- I-Premise
group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Discussion O
topics O
were O
predominantly O
raised O
by O
patients O
\/ O
relatives O
, O
regardless O
of O
arm O
allocation O
. O

Primary O
end O
point O
was O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

Compared B-Premise
with I-Premise
RELP I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
UM I-Premise
had I-Premise
significantly I-Premise
shorter I-Premise
duration I-Premise
of I-Premise
operation I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
shorter I-Premise
time I-Premise
periods I-Premise
to I-Premise
walk I-Premise
, I-Premise
return I-Premise
to I-Premise
daily I-Premise
activities I-Premise
, I-Premise
or I-Premise
sit I-Premise
without I-Premise
pain I-Premise
and I-Premise
to I-Premise
return I-Premise
to I-Premise
work I-Premise
or I-Premise
school I-Premise
, I-Premise
and I-Premise
fewer I-Premise
complications I-Premise
. I-Premise

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Included O
patients O
( O
n O
= O
80 O
) O
received O
supportive O
enteral O
or O
parenteral O
nutrition O
postoperatively O
at O
home O
corresponding O
to O
1000 O
kcal O
\/ O
d O
until O
the O
patients O
did O
not O
wish O
to O
continue O
with O
artificial O
nutrition O
for O
any O
reason O
. O

Postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
( O
N O
= O
5 O
, O
187 O
) O
were O
randomized O
to O
letrozole O
2 O
. O
5 O
mg O
or O
placebo O
once O
daily O
for O
5 O
years O
. O

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well I-Premise
- I-Premise
being I-Premise
. I-Premise

This B-Claim
procedure I-Claim
has I-Claim
been I-Claim
performed I-Claim
with I-Claim
the I-Claim
patient I-Claim
in I-Claim
the I-Claim
hypothyroid I-Claim
state I-Claim
to I-Claim
promote I-Claim
endogenous I-Claim
TSH I-Claim
stimulation I-Claim
and I-Claim
is I-Claim
often I-Claim
associated I-Claim
with I-Claim
hypothyroid I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self I-Claim
- I-Claim
assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well I-Claim
- I-Claim
being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

It O
is O
not O
known O
whether O
low O
- O
dose O
radioiodine O
( O
1 O
. O
1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high O
- O
dose O
radioiodine O
( O
3 O
. O
7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node O
- O
negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

Survival O
duration O
, O
disease O
- O
free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale O
- O
Global O
Fatigue O
"""" O
; O
"""" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
- O
of O
- O
Life O
Core O
30 O
Questionnaire O
, O
and O
CRF O
- O
associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

One O
hundred O
fifty O
- O
five O
patients O
with O
far O
- O
advanced O
CRC O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
Japanese O
Foundation O
for O
Multidisciplinary O
Treatment O
of O
Cancer O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

FACT O
- O
An O
, O
as O
administered O
to O
the O
survey O
population O
, O
displayed O
good O
psychometric O
properties O
and O
was O
able O
to O
discriminate O
between O
respondents O
with O
histories O
of O
specified O
illnesses O
, O
including O
anemia O
and O
cancer O
, O
and O
those O
without O
. O

The B-Premise
scapula I-Premise
- I-Premise
oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise

The B-Claim
role I-Claim
of I-Claim
three I-Claim
- I-Claim
drug I-Claim
combinations I-Claim
remains I-Claim
questionable I-Claim
in I-Claim
this I-Claim
subset I-Claim
of I-Claim
patients I-Claim
. I-Claim

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2 I-Premise
\/ I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
07 I-Premise
) I-Premise
. I-Premise

Between O
- O
group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O

RTOG O
89 O
- O
01 O
accrued O
75 O
patients O
, O
of O
whom O
73 O
were O
eligible O
and O
analyzable O
. O

Patients O
were O
assigned O
to O
12 O
weekly O
injections O
of O
subcutaneous O
epoetin O
alpha O
or O
placebo O
, O
targeting O
Hgb O
levels O
between O
120 O
and O
140 O
g O
\/ O
L O
. O

It B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full I-Claim
- I-Claim
breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

"""" B-Claim
Laying I-Claim
on I-Claim
of I-Claim
hands I-Claim
"""" I-Claim
resulted I-Claim
in I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
cancer I-Claim
- I-Claim
or I-Claim
cancer I-Claim
- I-Claim
therapy I-Claim
- I-Claim
associated I-Claim
symptoms I-Claim
. I-Claim

The B-Premise
ablation I-Premise
rate I-Premise
was I-Premise
equivalent I-Premise
between I-Premise
the I-Premise
( I-Premise
131 I-Premise
) I-Premise
I I-Premise
doses I-Premise
and I-Premise
between I-Premise
the I-Premise
thyrotropin I-Premise
- I-Premise
stimulation I-Premise
methods I-Premise
. I-Premise

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

Statistical O
significance O
was O
kept O
at O
p O
< O
0 O
. O
05 O
. O

We O
therefore O
studied O
the O
effects O
of O
a O
high O
- O
fat O
diet O
, O
particularly O
on O
body O
composition O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low O
- O
dose O
and O
high O
- O
dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

The O
primary O
endpoint O
was O
investigator O
- O
assessed O
overall O
response O
rate O
( O
ORR O
) O
"""" O
; O
"""" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

Sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
46 I-Premise
[ I-Premise
1 I-Premise
. I-Premise
03 I-Premise
- I-Premise
2 I-Premise
. I-Premise
06 I-Premise
] I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

An O
open O
, O
randomized O
study O
was O
performed O
to O
assess O
the O
effects O
of O
supportive O
pamidronate O
treatment O
on O
morbidity O
from O
bone O
metastases O
in O
breast O
cancer O
patients O
. O

Baseline O
characteristics O
, O
including O
LCSS O
scores O
, O
were O
well O
balanced O
between O
groups O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0 O
- O
1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

Advanced O
cancer O
patients O
and O
their O
caregivers O
( O
N O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three O
- O
session O
) O
or O
extensive O
( O
six O
- O
session O
) O
intervention O
or O
control O
. O

Both O
MLD O
with O
compression O
bandage O
( O
complex O
decongestive O
therapy O
) O
group O
( O
Group O
I O
, O
n O
= O
15 O
) O
and O
IPC O
with O
SLD O
group O
( O
Group O
II O
, O
n O
= O
15 O
) O
received O
treatment O
for O
LE O
3 O
days O
in O
a O
week O
and O
every O
other O
day O
for O
6 O
weeks O
. O

There O
are O
few O
randomized O
controlled O
trials O
on O
the O
effectiveness O
of O
palliative O
care O
interventions O
to O
improve O
the O
care O
of O
patients O
with O
advanced O
cancer O
. O

To O
compare O
dose O
- O
volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS O
\/ O
EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

Quality B-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
declined I-Premise
significantly I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
. I-Premise

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

To O
analyze O
the O
prospectively O
collected O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90 O
- O
03 O
and O
91 O
- O
11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and O
\/ O
or O
overall O
survival O
( O
OS O
) O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM O
- O
treated O
patients O
versus O
PLD O
- O
treated O
patients O
( O
P O
= O
. O
007 O
) O
. O

( O
600 O
mg O
\/ O
m O
( O
2 O
) O
day O
1 O
- O
28 O
of O
a O
56 O
- O
day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i O
. O
v O
. O
) O

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer I-Claim
- I-Claim
term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient I-Claim
- I-Claim
rated I-Claim
outcomes I-Claim
. I-Claim

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
= I-Premise
2 I-Premise
. I-Premise
13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
. I-Premise
41 I-Premise
to I-Premise
3 I-Premise
. I-Premise
20 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

Treatment B-Premise
toxicity I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
and I-Premise
intestinal I-Premise
adhesion I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
study I-Premise
groups I-Premise
. I-Premise

OS B-Premise
, I-Premise
PFS I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
RR I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6 I-Premise
- I-Premise
minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ I-Premise
- I-Premise
C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

Parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition I-Claim
- I-Claim
related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual O
- O
standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
0 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
0 I-Premise
. I-Premise
9 I-Premise
to I-Premise
0 I-Premise
. I-Premise
1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65 I-Claim
- I-Claim
175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient O
- O
tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

Two O
million O
people O
across O
the O
U O
. O
K O
. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long O
- O
term O
condition O
. O

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short I-Claim
- I-Claim
term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
Spitzer I-Premise
' I-Premise
s I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise

Compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse I-Claim
- I-Claim
led I-Claim
, I-Claim
palliative I-Claim
care I-Claim
- I-Claim
focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
ICU I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
0 I-Premise
. I-Premise
40 I-Premise
to I-Premise
5 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
2 I-Premise
. I-Premise
8 I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

The B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27 I-Premise
\/ I-Premise
97 I-Premise
and I-Premise
27 I-Premise
\/ I-Premise
103 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
absolute I-Premise
difference I-Premise
1 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
- I-Premise
10 I-Premise
. I-Premise
7 I-Premise
% I-Premise
to I-Premise
13 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

Baseline B-Premise
characteristics I-Premise
were I-Premise
comparable I-Premise
for I-Premise
both I-Premise
groups I-Premise
, I-Premise
except B-Premise
that I-Premise
more I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
were I-Premise
assigned I-Premise
to I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise

Among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19 I-Premise
\/ I-Premise
54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+ I-Premise
\/ I-Premise
- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
the I-Premise
population I-Premise
norm I-Premise
and I-Premise
clinical I-Premise
trial I-Premise
data I-Premise
showed I-Premise
that I-Premise
treatment I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
resulted I-Premise
in I-Premise
clinically I-Premise
meaningful I-Premise
as I-Premise
well I-Premise
as I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

Survival B-Premise
without I-Premise
performance I-Premise
- I-Premise
status I-Premise
deterioration I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low I-Premise
- I-Premise
frequency I-Premise
low I-Premise
- I-Premise
intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
anthracycline I-Claim
- I-Claim
pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0 I-Premise
. I-Premise
52 I-Premise
- I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
MBC I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim

After B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
TS I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non I-Claim
- I-Claim
resectable I-Claim
mCRC I-Claim
. I-Claim

Grade B-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
cytokine I-Premise
- I-Premise
treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
medroxyprogesterone I-Premise
- I-Premise
treated I-Premise
patients I-Premise
. I-Premise

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

EGFR B-Claim
- B-Claim
mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild I-Claim
- I-Claim
type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
self I-Claim
- I-Claim
directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well I-Claim
- I-Claim
being I-Claim
in I-Claim
older I-Claim
long I-Claim
- I-Claim
term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

The B-Premise
HgB I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+ I-Premise
5 I-Premise
. I-Premise
1 I-Premise
compared I-Premise
with I-Premise
- I-Premise
2 I-Premise
. I-Premise
1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16 I-Premise
. I-Premise
9 I-Premise
and I-Premise
17 I-Premise
. I-Premise
0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59 I-Premise
. I-Premise
62 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27 I-Premise
. I-Premise
28 I-Premise
% I-Premise
and I-Premise
27 I-Premise
. I-Premise
93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

Patients B-Premise
with I-Premise
UM I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise

EBRT B-Claim
for I-Claim
endometrial I-Claim
cancer I-Claim
is I-Claim
associated I-Claim
with I-Claim
long I-Claim
- I-Claim
term I-Claim
urinary I-Claim
and I-Claim
bowel I-Claim
symptoms I-Claim
and I-Claim
lower I-Claim
physical I-Claim
and I-Claim
role I-Claim
- I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
even I-Claim
15 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU I-Claim
\/ I-Claim
LV I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first I-Claim
- I-Claim
line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
. I-Claim

No B-Premise
difference I-Premise
in I-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
( I-Premise
70 I-Premise
% I-Premise
vs I-Premise
. I-Premise
66 I-Premise
% I-Premise
) I-Premise
or I-Premise
median I-Premise
survival I-Premise
time I-Premise
( I-Premise
19 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
. I-Premise
4 I-Premise
months I-Premise
) I-Premise
between I-Premise
the I-Premise
surgery I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
DOX I-Premise
in I-Premise
OS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
66 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
48 I-Premise
to I-Premise
0 I-Premise
. I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT I-Premise
- I-Premise
SOMA I-Premise
scale I-Premise
. I-Premise

A B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone I-Claim
- I-Claim
resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative I-Claim
- I-Claim
intent I-Claim
head I-Claim
- I-Claim
neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12 I-Premise
. I-Premise
3 I-Premise
( I-Premise
2 I-Premise
. I-Premise
1 I-Premise
- I-Premise
89 I-Premise
. I-Premise
2 I-Premise
) I-Premise
and I-Premise
10 I-Premise
. I-Premise
3 I-Premise
( I-Premise
0 I-Premise
. I-Premise
3 I-Premise
- I-Premise
91 I-Premise
. I-Premise
7 I-Premise
+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux I-Claim
- I-Claim
en I-Claim
- I-Claim
Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

Adding B-Claim
docetaxel I-Claim
to I-Claim
CF I-Claim
significantly I-Claim
improved I-Claim
TTP I-Claim
, I-Claim
survival I-Claim
, I-Claim
and I-Claim
response I-Claim
rate I-Claim
in I-Claim
gastric I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
but I-Claim
resulted I-Claim
in I-Claim
some I-Claim
increase I-Claim
in I-Claim
toxicity I-Claim
. I-Claim

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43 I-Premise
. I-Premise
1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
versus I-Premise
44 I-Premise
. I-Premise
5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum I-Premise
- I-Premise
adjusted I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
18 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
885 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan I-Premise
- I-Premise
Meier I-Premise
analysis I-Premise
. I-Premise

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

However B-Claim
, I-Claim
presuming I-Claim
these I-Claim
improvements I-Claim
were I-Claim
caused I-Claim
by I-Claim
the I-Claim
individualized I-Claim
homeopathic I-Claim
approach I-Claim
, I-Claim
the I-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
clearly I-Claim
that I-Claim
the I-Claim
specific I-Claim
effect I-Claim
of I-Claim
the I-Claim
remedy I-Claim
added I-Claim
further I-Claim
to I-Claim
the I-Claim
nonspecific I-Claim
effects I-Claim
of I-Claim
the I-Claim
consultation I-Claim
. I-Claim

There B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non I-Claim
- I-Claim
hematological I-Claim
toxicities I-Claim
. I-Claim

SNBM B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
RAC I-Claim
. I-Claim

Differences B-Claim
in I-Claim
chemotherapy I-Claim
scheduling I-Claim
, I-Claim
pre I-Claim
- I-Claim
existing I-Claim
morbidity I-Claim
, I-Claim
and I-Claim
toxicity I-Claim
are I-Claim
important I-Claim
in I-Claim
individualizing I-Claim
therapy I-Claim
. I-Claim

The B-Claim
two I-Claim
chemotherapy I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
similar I-Claim
effectiveness I-Claim
in I-Claim
symptom I-Claim
palliation I-Claim
when I-Claim
evaluated I-Claim
with I-Claim
C30 I-Claim
addendum I-Claim
of I-Claim
EORTC I-Claim
QOL I-Claim
questionnaire I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

Gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
RP I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim

Taking B-Claim
a I-Claim
pre I-Claim
- I-Claim
treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

The B-Claim
present I-Claim
analysis I-Claim
confirms I-Claim
that I-Claim
survival I-Claim
of I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
HRPC I-Claim
is I-Claim
significantly I-Claim
longer I-Claim
after I-Claim
treatment I-Claim
with I-Claim
D3P I-Claim
than I-Claim
with I-Claim
MP I-Claim
. I-Claim

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

The B-Claim
3 I-Claim
- I-Claim
weekly I-Claim
irinotecan I-Claim
schedule I-Claim
also I-Claim
seemed I-Claim
advantageous I-Claim
in I-Claim
terms I-Claim
of I-Claim
grade I-Claim
3 I-Claim
\/ I-Claim
4 I-Claim
diarrhea I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
overall I-Claim
survival I-Claim
and I-Claim
patient I-Claim
convenience I-Claim
, I-Claim
but B-Claim
the I-Claim
study I-Claim
was I-Claim
not I-Claim
designed I-Claim
to I-Claim
detect I-Claim
differences I-Claim
in I-Claim
these I-Claim
parameters I-Claim
. I-Claim

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self I-Claim
- I-Claim
reported I-Claim
end I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

